Literature DB >> 21455322

Diagnosis and therapy of ascites in liver cirrhosis.

Erwin Biecker.   

Abstract

Ascites is one of the major complications of liver cirrhosis and is associated with a poor prognosis. It is important to distinguish noncirrhotic from cirrhotic causes of ascites to guide therapy in patients with noncirrhotic ascites. Mild to moderate ascites is treated by salt restriction and diuretic therapy. The diuretic of choice is spironolactone. A combination treatment with furosemide might be necessary in patients who do not respond to spironolactone alone. Tense ascites is treated by paracentesis, followed by albumin infusion and diuretic therapy. Treatment options for refractory ascites include repeated paracentesis and transjugular intrahepatic portosystemic shunt placement in patients with a preserved liver function. Potential complications of ascites are spontaneous bacterial peritonitis (SBP) and hepatorenal syndrome (HRS). SBP is diagnosed by an ascitic neutrophil count > 250 cells/mm(3) and is treated with antibiotics. Patients who survive a first episode of SBP or with a low protein concentration in the ascitic fluid require an antibiotic prophylaxis. The prognosis of untreated HRS type 1 is grave. Treatment consists of a combination of terlipressin and albumin. Hemodialysis might serve in selected patients as a bridging therapy to liver transplantation. Liver transplantation should be considered in all patients with ascites and liver cirrhosis.

Entities:  

Keywords:  Ascites; Diuretics; Hepatorenal syndrome; Liver cirrhosis; Sodium balance; Spontaneous bacterial peritonitis; Transjugular intrahepatic portosystemic shunt

Mesh:

Substances:

Year:  2011        PMID: 21455322      PMCID: PMC3068258          DOI: 10.3748/wjg.v17.i10.1237

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  143 in total

1.  The North American Study for the Treatment of Refractory Ascites.

Authors:  Arun J Sanyal; Chris Genning; K Rajender Reddy; Florence Wong; Kris V Kowdley; Kent Benner; Timothy McCashland
Journal:  Gastroenterology       Date:  2003-03       Impact factor: 22.682

2.  Spontaneous bacterial peritonitis in asymptomatic outpatients with cirrhotic ascites.

Authors:  Luke T Evans; W Ray Kim; John J Poterucha; Patrick S Kamath
Journal:  Hepatology       Date:  2003-04       Impact factor: 17.425

3.  Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites.

Authors:  Javier Sola-Vera; Josep Miñana; Elena Ricart; Montserrat Planella; Begoña González; Xavier Torras; Jose Rodríguez; José Such; Sonia Pascual; Germán Soriano; Miguel Pérez-Mateo; Carlos Guarner
Journal:  Hepatology       Date:  2003-05       Impact factor: 17.425

4.  Survival in patients undergoing transjugular intrahepatic portosystemic shunt: ePTFE-covered stentgrafts versus bare stents.

Authors:  Bernhard Angermayr; Manfred Cejna; Franz Koenig; Franz Karnel; Franz Hackl; Alfred Gangl; Markus Peck-Radosavljevic
Journal:  Hepatology       Date:  2003-10       Impact factor: 17.425

5.  Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study.

Authors:  Gilles Pomier-Layrargues; Sarto C Paquin; Ziad Hassoun; Michel Lafortune; Albert Tran
Journal:  Hepatology       Date:  2003-07       Impact factor: 17.425

Review 6.  The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club.

Authors:  Kevin P Moore; Florence Wong; Pere Gines; Mauro Bernardi; Andreas Ochs; Francesco Salerno; Paolo Angeli; Michael Porayko; Richard Moreau; Guadelupe Garcia-Tsao; Wladimiro Jimenez; Ramon Planas; Vicente Arroyo
Journal:  Hepatology       Date:  2003-07       Impact factor: 17.425

7.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

8.  Five days of ceftriaxone to treat culture negative neutrocytic ascites in cirrhotic patients.

Authors:  Mevlut Baskol; Sebnem Gursoy; Gulden Baskol; Omer Ozbakir; Kadri Guven; Mehmet Yucesoy
Journal:  J Clin Gastroenterol       Date:  2003 Nov-Dec       Impact factor: 3.062

9.  Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety.

Authors:  Justiniano Santos; Ramon Planas; Albert Pardo; Rosa Durández; Eduard Cabré; Rosa Maria Morillas; Maria Luisa Granada; José Angel Jiménez; Enrique Quintero; Miquel Angel Gassull
Journal:  J Hepatol       Date:  2003-08       Impact factor: 25.083

10.  Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation.

Authors:  Gianni Testino; Carlo Ferro; Alessandro Sumberaz; Piergiorgio Messa; Nicola Morelli; Barbara Guadagni; Giorgio Ardizzone; Umberto Valente
Journal:  Hepatogastroenterology       Date:  2003 Nov-Dec
View more
  19 in total

1.  Cost-Effectiveness of Transjugular Intrahepatic Portosystemic Shunt versus Large-Volume Paracentesis in Refractory Ascites: Results of a Markov Model Incorporating Individual Patient-Level Meta-Analysis and Nationally Representative Cost Data.

Authors:  Sharon W Kwan; Stephen K Allison; Laura S Gold; David S Shin
Journal:  J Vasc Interv Radiol       Date:  2018-11-02       Impact factor: 3.464

Review 2.  Treatment and management of ascites and hepatorenal syndrome: an update.

Authors:  Kurt Lenz; Robert Buder; Lisbeth Kapun; Martin Voglmayr
Journal:  Therap Adv Gastroenterol       Date:  2015-03       Impact factor: 4.409

Review 3.  [Anesthesia with liver failure].

Authors:  Eva-Lotte Camboni-Schellenberg; Barbara Sinner
Journal:  Anaesthesist       Date:  2016-01       Impact factor: 1.041

4.  Rifaximin for the prevention of spontaneous bacterial peritonitis.

Authors:  Georgios N Kalambokis; Athanasia Mouzaki; Maria Rodi; Epameinondas V Tsianos
Journal:  World J Gastroenterol       Date:  2012-04-14       Impact factor: 5.742

5.  Young Man With Non-hypertensive Ascites of Unexpected Cause: When Ockham's Razor Is Not Sufficient.

Authors:  Julián Rondón-Carvajal; Jose C Alvarez-Payares; Natalia Arias-Madrid; Jeanneth Echeverri-Villegas; Laura Uribe-Zapata
Journal:  Cureus       Date:  2022-05-27

Review 6.  Outcomes of abdominal surgery in patients with liver cirrhosis.

Authors:  Juan C Lopez-Delgado; Josep Ballus; Francisco Esteve; Nelson L Betancur-Zambrano; Vicente Corral-Velez; Rafael Mañez; Antoni J Betbese; Joan A Roncal; Casimiro Javierre
Journal:  World J Gastroenterol       Date:  2016-03-07       Impact factor: 5.742

7.  Can serum albumin level affect the pharmacological action of tolvaptan in patients with liver cirrhosis? A post hoc analysis of previous clinical trials in Japan.

Authors:  Isao Sakaida; Koji Nakajima; Kiwamu Okita; Masatsugu Hori; Tohru Izumi; Masaya Sakurai; Yoshiyuki Shibasaki; Sayaka Tachikawa; Hidetsugu Tsubouchi; Hiromi Oka; Hiroyuki Kobayashi
Journal:  J Gastroenterol       Date:  2015-02-18       Impact factor: 7.527

Review 8.  Ascitic Fluid Analysis in the Differential Diagnosis of Ascites: Focus on Cirrhotic Ascites.

Authors:  Lin-Lin Huang; Harry Hua-Xiang Xia; Sen-Lin Zhu
Journal:  J Clin Transl Hepatol       Date:  2014-03-15

9.  Strain of experimental animals and modulation of nitric oxide pathway: their influence on development of renal failure in an experimental model of hepatorenal syndrome.

Authors:  Marek Saracyn; Janusz Patera; Janusz Kocik; Marek Brytan; Robert Zdanowski; Arkadiusz Lubas; Wojciech Kozłowski; Zofia Wańkowicz
Journal:  Arch Med Sci       Date:  2012-07-04       Impact factor: 3.318

10.  Efficacy and safety of alternating norfloxacin and rifaximin as primary prophylaxis for spontaneous bacterial peritonitis in cirrhotic ascites: a prospective randomized open-label comparative multicenter study.

Authors:  M Assem; M Elsabaawy; M Abdelrashed; S Elemam; S Khodeer; W Hamed; A Abdelaziz; G El-Azab
Journal:  Hepatol Int       Date:  2015-12-10       Impact factor: 9.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.